Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-05-17
1998-02-03
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
435 721, 530350, 530395, G01N 3353, G01N 33543, G01N 33561, C07K 1300
Patent
active
057144710
ABSTRACT:
Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae I and II: ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, cyclohexyl or cyclohexylmethyl; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.8 is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is preferably an .alpha.-ketoester or .alpha.-ketoamide.
REFERENCES:
patent: 4044126 (1977-08-01), Cook et al.
patent: 4364923 (1982-12-01), Cook et al.
patent: 4414209 (1983-11-01), Cook et al.
patent: 4666829 (1987-05-01), Glenner et al.
patent: 4701407 (1987-10-01), Appel
patent: 4840935 (1989-06-01), Wagnon et al.
patent: 5015570 (1991-05-01), Scangos et al.
patent: 5034376 (1991-07-01), Hoover
patent: 5039511 (1991-08-01), Quay et al.
patent: 5081284 (1992-01-01), Higuchi et al.
patent: 5200339 (1993-04-01), Abraham
patent: 5213962 (1993-05-01), van Nostrandt et al.
patent: 5218100 (1993-06-01), Muller-Hill et al.
patent: 5223633 (1993-06-01), Hoppe et al.
patent: 5231000 (1993-07-01), Majocha et al.
patent: 5234814 (1993-08-01), Card et al.
patent: 5242932 (1993-09-01), Gandy et al.
patent: 5270165 (1993-12-01), van Nostrandt et al.
patent: 5284828 (1994-02-01), Hemmi et al.
patent: 5374623 (1994-12-01), Zimmerman et al.
patent: 5427931 (1995-06-01), Van Nostrand et al.
patent: 5430022 (1995-07-01), Hemmi et al.
patent: 5441870 (1995-08-01), Seubert et al.
patent: 5470833 (1995-11-01), Ishikawa et al.
patent: 5496928 (1996-03-01), Ishikawa et al.
patent: 5508167 (1996-04-01), Roses et al.
patent: 5538845 (1996-07-01), Knops et al.
patent: 5547841 (1996-08-01), Marrotta et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 5605811 (1997-02-01), Seubert et al.
patent: 5612486 (1997-03-01), McConlogue et al.
Siman et al., Proteolytic processing of .beta.-Amyloid precursor by calpain I, J.Neurosci. 10(7):2400-2411 (1990).
Lannfelt et al. Decreased .alpha.-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nature Med. 1:829-832 (1995).
Sisodia et al. Cellular and molecular biology of Alzheimer's disease and animal models. Neurodegen. Dis. 5:59-68 (1995).
Price et al. Alzheimer's disease and the prion disorders amyloid .beta. protein and prion protein amyloidoses Proc. Natl. Acad. Sci. U.S.A. 90: 6381-6384 (1993).
Smith et al. The molecular pathology of Alzheimer's disease: are we any closer to understanding the neurodegenerative process. Neuropathol. Appl. Neurobiol. 20: 322-338 (1994).
de Lustig et al. Peripheral markers and diagnostic criteria in Alzheimer's disease: critical evaluations. Rev. Neurosci. 5:213-225 (1994).
Dresse et al. Towards a pharmacological approach to Alzheimer's disease based on the molecular biology of the amyloid precursor protein. Life Sci. 55:2179-2187 (1994).
Angelastro, et al., "Inhibition of Human Neutrophil Elastase with Peptidyl Electrophilic Ketones," J. Med. Chem., 37:4538-4554 (1994).
Angliker, et al., "Inactivation of calpain by peptidyl fluoromethyl ketones," J. Med. Chem., 35:216-220 (1992).
Arner, et al., "1-Chloro-2,4-dinitrobenzene is an Irreversible Inhibitor of Human Thioredoxin Reductase," J. Biol. Chem., 270(8):3479-3482 (1995).
Bodanszky and Bodanszky, "I. Protecting Groups 5. The tert.Butyloxycarbonyl (Boc) Group," The Practice of Peptide Synthesis, Springer-Verlag, pp. 18-20 (1984). Human Renin Inhibitory Activity," J. Med. Chem., 33:2335-2342 (1990).
Breaux and Bender, "The binding of specific and non-specific aldehyde substrate analogs to .alpha.-chymotrypsin," FEBS Letters, 56(1):81-84 (1975).
Buxbaum, et al., "Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer .beta./A4 amyloid protein precursor," Proc. Natl. Acad. Sci. USA, 89:10075-10078 (1992).
Cai, et al., "Release of excess amyloid .beta. protein from a mutant amyloid .beta. protein precursor," Science, 259:514-516 (1993).
Caporaso, et al., "Chloroquine inhibits intracellular degradation but not secretion of Alzheimer .beta./A4 amyloid precursor protein," Proc. Natl. Acad. Sci. USA, 89:2252-2256 (1992).
Citron, et al., "Mutation of the .beta.-amyloid precursor protein in familial Alzheimer's disease increases .beta.-protein production," Nature, 360:672-674 (1992).
Cooper, et al., "X-ray Crystallographic Analysis of Inhibition of Endothiapepsin by Cyclohexyl Renin Inhibitors," Biochemistry, 31:8142-8150 (1992).
Cooper, et al., "X-ray Studies of Aspartic Proteinase-Statine Inhibitor Complexes," Biochemistry, 28:8596-8603 (1989).
Crawford, et al., "The design of peptidyldiazomethane inhibitors to distinguish between the cysteine proteinases calpain II, cathepsin L and cathepsin B," J. Biochem., 253:751-758 (1988).
Crawford, "Protein and peptide inhibitors of calpains," Intracellular Calcium-Dependent Proteolysis, Chapter 5, pp. 75-89, date is not available.
Davis, et al., "A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease," New England J. of Med., 327(18):1253-1259 (1992).
De Strooper, et al., "Basolateral Secretion of Amyloid Precursor Protein in Madin-Darby Canine Kidney Cells is Ditributed by Alterations of Intracellular pH and by Introducing a Mutation Associated with Familial Alzheimer's Disease," J. Biol. Chem., 270(8):4058-4065 (1995).
Dess and Martin, "Readily accessible 12-I-5.sup.1 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones," J. Org. Chem., 48:4155-4156 (1983).
Dolle, et al., "Aspartyl .alpha.-((1-Phenyl-3-(trifluoromethyl)-pyrazol-5-yl)oxy)methyl Ketones as Interleukin-1.beta. Converting Enzyme Inhibitors. Significance of the P.sub.1 and P.sub.3 Amido Nitrogens for Enzyme-Peptide Inhibitor Binding," J. Med. Chem., 37(23):3863-3866 (1994).
Esch, et al., "Cleavage of amyloid .beta. peptide during constitutive processing of its precursor," Science, 24:1122-1124 (1990).
Farlow, et al., "Low cerebrospinal-fluid concentrations of soluble amyloid .beta.-protein precursor in hereditary Alzheimer's disease," Lancet, 340:453-454 (1992).
Fieser and Fieser, Reagents for Organic Synthesis, John Wiley and Sons, New York, 1:145, date is not available.
Figueiredo-Pereira, et al., "Comparison of the effect of calpain inhibitors on two extralysosomal proteinases: The multicatalytic proteinase complex and m-calpain," J. Neurochemistry, 62(5):1989-1994 (1994).
Figueiredo-Pereira, et al., "A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell," J. Neurochemistry, 63(4):1578-1581 (1994).
Folstein, et al., "Mini-mental state"--A practical method for grading the cognitive state of patients for the clinician, J. Psychiat. Res., 12:189-198 (1975).
Francis, et al., "Soluble .beta.-amyloid precursor protein and pyramidal neuron loss," Lancet, 341:431 (1993).
Gisin, "The preparation of Merrifield-resins through total esterification with cesium salts," Helvetica Chimica Acta, 56(5):1476-1482 (1973).
Glenner and Wong, "Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein," Biochem. and Biophys. Res. Comm., 120(3):885-890 (1984).
Grubb, et al., "Abnormal metabolism of .gamma.-trace alkaline microprotein--The basic defect in hereditary cerebral hemorrhage with amyloidosis," N. England J. of Med., 311(24):1547-1549 (1984).
Haas, et al., "Targeting of cell-surface .beta.-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments," Nature, 357:500-503 (1992).
Hardy, "The genetics of Alzheimer's disease," Neurosci. Facts, 3
Rowe Blake Alan
Siegel Robert Steven
Wagner Steven Lee
Seidman Stephanie L.
SIBIA Neurosciences Inc.
Touzeau P. Lynn
Tsang Cecilia J.
LandOfFree
Peptide and peptide analog protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide and peptide analog protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide and peptide analog protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-662426